Displaying 61 - 80 of 498
Dissenting Statement of Commissioner Christine S. Wilson
Dissenting Remarks of Commissioner Noah Joshua Phillips Regarding the Commission's Issuance of Seven Omnibus Resolution
Louisiana Real Estate Appraisers Board; Analysis of Agreement Containing Consent Order To Aid Public Comment
Louisiana Real Estate Appraisers Board Agrees to Settle FTC Charges that It Fixed Prices for Appraisal Services in Louisiana
Statement of Commissioners Christine S. Wilson and Noah Joshua Phillips Regarding the Federal Trade Commission's Report to Congress on Rebate Walls
Statement of Acting Chairwoman Rebecca Kelly Slaughter Regarding the Federal Trade Commission’s Report to Congress on Rebate Walls
Statement of Commissioner Rohit Chopra Regarding the Commission's Report on Pharmacy Benefit Manager Rebate Walls
Federal Trade Commission Sends Report to Congress on Rebate Walls
FTC Returns Nearly $60 Million to Those Suffering from Opioid Addiction Who Were Allegedly Overcharged in Suboxone Film Scheme
Impax Laboratories, Inc., In the Matter of
The FTC's administrative complaint against Impax charges that in 2010, Impax and Endo Pharmaceuticals Inc. illegally agreed that Impax would not compete by marketing a generic version of Endo’s Opana ER until January 2013. In exchange, Endo paid Impax more than $112 million.
Endo agreed to settle these charges in a stipulated order entered in federal court. See FTC v. Allergan plc, and Watson Laboratories, Inc. et al.
The Commission’s 2019 opinion held that the FTC staff had proven that the agreement between Impax and Endo Pharmaceuticals Inc. violated Section 5 of the Federal Trade Commission Act. The Commission’s opinion reversed Chief Administrative Law Judge D. Michael Chappell’s initial decision.
In April 2021, the U.S. Court of Appeals for the Fifth Circuit upheld the Commission’s opinion.
Statement by Acting Chairwoman Rebecca Kelly Slaughter on Agency’s Decision not to Petition Supreme Court for Review of Qualcomm Case
Prepared Statement of Federal Trade Commission Acting Chair Rebecca Kelly Slaughter Concerning "Reviving Competition Part 3: Strengthening the Laws to Address Monopoly Power"
Endo Pharmaceuticals Inc./Amneal Pharmaceuticals, Inc.
The FTC is suing Endo Pharmaceuticals, Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The complaint charges the defendants with violating Sections 1 and 2 of the Sherman Act, which constitutes unfair methods of competition in violation of Section 5 of the FTC Act. Specifically, Endo, Impax, and Amneal are charged with entering into an illegal agreement in restraint of trade, and Amneal is charged with monopolization of the oxymorphone ER market. The complaint was filed in the U.S. District Court for the District of Columbia on Jan. 25, 2021.
FTC Again Charges Endo and Impax with Illegally Preventing Competition in U.S. Market for Oxymorphone ER
FTC Sues Facebook for Illegal Monopolization
FTC Requests Rehearing En Banc of Qualcomm Appeals Panel Decision
Displaying 61 - 80 of 498